U.S. Epinephrine Market Size, Share & COVID-19 Impact Analysis, By Product Type (Auto-injectors, Pre-filled Syringes, and Ampoules & Vials), By Application (Anaphylaxis, Cardiac Arrest, Respiratory Disorders, and Others), By Distribution Channel (Hospital Pharmacy and Retail & Online Pharmacy), and Country Forecast, 2023-2030

The U.S. epinephrine market size was worth USD 1.07 billion in 2022 and is projected to grow at a CAGR of 10.8% during the forecast period.

Epinephrine, also known as adrenaline, is utilized for severe allergic reactions (anaphylaxis) and asthma attacks. Additionally, this medication is administered during cardiopulmonary resuscitation (CPR) to reverse cardiac arrest. The increasing prevalence of these diseases is driving the demand for medications, consequently fueling the growth of the U.S. epinephrine market.

• For instance, according to data published by the Asthma and Allergy Foundation of America in 2023, over 100 million people in the U.S. suffer from some form of allergy annually.

The sudden outbreak of the COVID-19 pandemic had a negative impact on the market in 2020. The market experienced a decline due to a limited number of patient visits, reduced diagnosis of anaphylaxis, and disruptions in drug manufacturing.

LATEST TRENDS

Increasing Emphasis of Market Players on New Product Launches

The burden of anaphylaxis has significantly increased in the U.S. According to the Centers for Disease Control and Prevention (CDC), approximately 1 in 3 adults and 1 in 4 children were reported to have food allergies, eczema, or seasonal allergies in 2021.

This heightened disease burden has escalated the demand for effective therapeutics. To better manage the condition and meet the increasing demand for new treatments, market players have been focusing on launching novel and effective therapeutics.

• For instance, in March 2023, Daiichi Sankyo, Inc., through its subsidiary American Regent, Inc., launched sulfite-free Epinephrine Injection, USP, indicated for emergency treatment of type I allergic reactions.

DRIVING FACTORS

Increasing Prevalence of Cardiac Arrest and Allergic Reactions to Fuel Market Growth

The prevalence of cardiac arrest, respiratory diseases, seasonal allergies, food allergies, and others is increasing significantly. Epinephrine is the primary drug administered for treating cardiac arrest and anaphylaxis.

• For instance, according to the Centers for Disease Control and Prevention, approximately 24.96 million people in the U.S. were suffering from asthma in 2021.

The rising prevalence of these diseases is leading to a growing demand for epinephrine injectors in the country. This, coupled with the introduction of new cost-competitive products in the market, is driving the U.S. epinephrine market growth.

Request a Free sample to learn more about this report.

In 2022, around 26.0 million people were affected by asthma, and 13.5 million suffered from anaphylaxis.

RESTRAINING FACTORS

Certain Risk Factors Associated With the Use of the Product and its High Cost May Hamper Market Growth

Epinephrine effectively treats life-threatening allergic reactions caused by insect bites, medications, food, and other triggers. However, risk factors associated with this drug, such as hypertension, chest pain, anxiety, dizziness, and others, are limiting its adoption among the population.

Moreover, treatment with epinephrine can be costly. For instance, Primatene Mist, an inhaler used to treat asthma, can cost around USD 3.22 per mg. In contrast, an albuterol inhaler, an alternate option for asthma treatment, costs approximately USD 0.28 per ml. The high cost of these therapeutics is restricting their adoption among the U.S. population.

Furthermore, stringent government regulations for new product approvals are limiting the availability of new drugs in the market. For example, in June 2023, the Food and Drug Administration (FDA) extended the New Drug Application (NDA) review period for Neffy, an epinephrine nasal spray. This delay affected the approval and commercialization of Neffy.

Therefore, stringent government regulations, high costs, and associated risk factors are limiting the adoption of epinephrine injectors in the country.

SEGMENTATION

By Product Type Analysis

By product type, the market is divided into pre-filled syringes, ampoules & vials, and auto-injectors.

The auto-injectors segment led the market in 2022 and is expected to grow significantly at a CAGR during the forecast period. This growth is attributed to the advantages of using auto-injectors, including convenient usability, fast absorption, safety, and other factors.

The pre-filled syringes segment is projected to experience substantial growth at a CAGR during the forecast period. Several benefits linked to the use of pre-filled syringes, such as the elimination of dosage errors, reconstitution steps, avoidance of overfilling expensive drugs, and other advantages, have been crucial in driving patients' preference for these products.

By Application Analysis

Based on application, the market is categorized into cardiac arrest, respiratory disorders, anaphylaxis, and others.

The anaphylaxis segment held the market dominance in 2022, primarily due to the increasing prevalence of anaphylaxis in the country. For example, as reported by the Asthma and Allergy Foundation of America, 2 in 50 Americans suffer from anaphylaxis.

The respiratory disorders segment is anticipated to exhibit significant growth at a CAGR during the forecast period. This growth is driven by the escalating burden of respiratory disorders such as asthma, coupled with the growing awareness surrounding the use of epinephrine inhalers for their treatment.

By Distribution Channel Analysis

By distribution channel, the market is divided into retail & online pharmacy and hospital pharmacy.

The retail & online pharmacy segment held market dominance in 2022, driven by the increasing presence of retail pharmacies selling these drug injectors and enhanced accessibility to these injectors through online platforms.

The hospital pharmacy segment is projected to experience substantial growth at a significant CAGR during the forecast period. This growth is attributed to the rising number of hospital admissions related to allergic reactions, respiratory disorders, and other medical conditions.

KEY INDUSTRY PLAYERS

Market players such as Teva Pharmaceutical Industries Ltd., Amneal Pharmaceuticals LLC., and Viatris Inc. held a significant portion of the U.S. epinephrine market share in 2022. The strong presence of companies such as Teva Pharmaceutical Industries Ltd. stems from the increased sales of their generic versions of brands such as EpiPen and EpiPen Jr.

Other key players in the market include Viatris Inc., kaleo, Inc., and Bausch Health Companies Inc. These players are increasingly focusing on partnerships and collaborations to bolster the distribution of their products, a move anticipated to enhance their market share during the forecast period.

• For instance, in August 2022, kaleo, Inc. entered a ten-year commercialization agreement with Valeo Pharma, a Canada-based pharmaceutical company, to expand the distribution of its product ALLERJECT, an epinephrine auto injector.

LIST OF KEY COMPANIES PROFILED:

• Teva Pharmaceutical Industries Ltd. (Israel)


• Viatris Inc. (U.S.)


• kaleo, Inc. (U.S.)


• Bausch Health Companies Inc. (Canada)


• Amneal Pharmaceuticals LLC. (U.S.)


• USWM, LLC. (U.S.)


• BIOPROJET (France)


• ALK-Abelló A/S (Denmark)

KEY INDUSTRY DEVELOPMENTS:

• July 2022 – ARS Pharmaceuticals merged with Silverback Therapeutics for regulatory approval and commercialization of neffy, an epinephrine nasal spray.


• November 2020 – Adamis Pharmaceuticals Corporation announced that it has entered a commercialization and distribution agreement with USWM, LLC for its product SYMJEPI, indicated for allergic emergencies. This partnership strengthened the company’s distribution network for SYMJEPI.


• August 2019 – Teva Pharmaceutical Industries Ltd. commercialized the generic version of the EpiPen auto-injector in the U.S. at USD 300 (for a set of 2) in retail pharmacies.

REPORT COVERAGE

An Infographic Representation of U.S. Epinephrine Market

View Full Infographic

To get information on various segments, share your queries with us

The U.S. market report provides a detailed analysis including market segmentation, key points such as an overview of technological advancements, market dynamics, and the product portfolio of the key players operating in the market. In addition, the market analysis includes new product launches, key industry developments such as mergers, collaborations, & acquisitions, and the impact of the COVID-19 pandemic on the market. Besides this, the report also offers insights into the market trends and highlights key industry dynamics. In addition to the aforementioned factors, it encompasses several factors that have contributed to the growth of the market over recent years.

Report Scope & Segmentation